Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial

PURPOSE: To assess the efficacy and exploratory biomarkers of continuing palbociclib plus endocrine therapy (ET) beyond progression on prior palbociclib-based regimen in patients with hormone receptor–positive/HER2-negative (HR(+)/HER2(−)) advanced breast cancer (ABC). PATIENTS AND METHODS: The mult...

Descripción completa

Detalles Bibliográficos
Autores principales: Albanell, Joan, Pérez-García, José Manuel, Gil-Gil, Miguel, Curigliano, Giuseppe, Ruíz-Borrego, Manuel, Comerma, Laura, Gibert, Joan, Bellet, Meritxell, Bermejo, Begoña, Calvo, Lourdes, de la Haba, Juan, Espinosa, Enrique, Minisini, Alessandro Marco, Quiroga, Vanesa, Santaballa Bertran, Ana, Mina, Leonardo, Bellosillo, Beatriz, Rojo, Federico, Menéndez, Silvia, Sampayo-Cordero, Miguel, Popa, Crina, Malfettone, Andrea, Cortés, Javier, Llombart-Cussac, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811162/
https://www.ncbi.nlm.nih.gov/pubmed/36165912
http://dx.doi.org/10.1158/1078-0432.CCR-22-1281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811162/
https://www.ncbi.nlm.nih.gov/pubmed/36165912
http://dx.doi.org/10.1158/1078-0432.CCR-22-1281

Ejemplares similares